People: StemCells Inc (STEM.O)

STEM.O on Consolidated Issue listed on NASDAQ Global Market

1.17USD
9 Feb 2010
Price Change (% chg)

$0.01 (+0.86%)
Prev Close
$1.16
Open
$1.16
Day's High
$1.18
Day's Low
$1.12
Volume
2,017,357
Avg. Vol
1,654,188
52-wk High
$2.64
52-wk Low
$1.02

view people for:

Summary

Name Age Since Current Position
Schwartz, John 74 1998 Chairman of the Board
McGlynn, Martin 62 2001 President, Chief Executive Officer, Director
Young, Rodney 46 2006 Chief Financial Officer, Vice President - Finance and Administration
Tsukamoto, Ann 56 2008 Executive Vice President - Research and Development
Craig, Stewart 47 2008 Senior Vice President - Development and Operations
Stratton, Kenneth 40 2007 General Counsel
Weissman, Irving 69 1997 Director
Perlmutter, Roger 56 2000 Director
Levy, Ricardo 64 2001 Director
Bjerkholt, Eric 49 2004 Director
» Insider Trading

Biographies

Name Description
Schwartz, John Dr. John J. Schwartz serves as Director of StemCells Inc since since December 1998 and was elected the Chairman of the Board at the same time. He is the former president and chief executive officer of SyStemix, Inc. Dr. Schwartz is currently the president of Quantum Strategies Management Company, a registered investment advisor located in Palo Alto, California. Prior to his positions at SyStemix, he served as assistant professor, vice president and general counsel at Stanford University in California. Dr. Schwartz graduated from Harvard Law School in 1958 and received his Ph.D. degree in physics from the University of Rochester in 1965.
McGlynn, Martin Mr. Martin M. McGlynn serves as President, Chief Executive Officer, Director of StemCells Inc. He joined the company on January 15, 2001, when he was appointed president and chief executive officer of the company and of its wholly-owned subsidiary, StemCells California, Inc. He was elected to the Board of Directors in February 2001. Mr. McGlynn began his career with Becton Dickinson, Ireland Ltd., and spent 8 years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as the general manager of Abbott Ireland Ltd., the president and general manager of Abbott Canada Ltd. and the vice president of Abbott International Ltd. In 1990, he joined the BOC Group as the president of Anaquest, Inc., a company focused on anesthesia and acute care pharmaceuticals. From 1994 until he joined StemCells, Mr. McGlynn was the president and chief executive officer of Pharmadigm, Inc., a privately held company in Salt Lake City, Utah, engaged in research and development in the fields of inflammation and genetic immunization. Mr. McGlynn is a native of Dublin, Ireland. He received a Bachelor of Commerce degree from University College, Dublin, Ireland in 1968, a diploma in industrial engineering from the Irish Institute of Industrial Engineering in 1970, and a diploma in production planning from the University of Birmingham, England in 1971. He is a former member of the board of directors of the Confederation of Irish Industries and the Pharmaceutical Manufacturers Association of Canada.
Young, Rodney Mr. Rodney K.B. Young serves as Chief Financial Officer, Vice President - Finance and Administration of StemCells Inc. He joined StemCells in September 2005 as Chief Financial Officer and Vice President, Finance. In November 2006 he became CFO and Vice President, Finance and Administration. He is responsible for functions that include Finance, Information Technology and Investor Relations. From 2003 to 2005, Mr. Young was Chief Financial Officer and a director of Extropy Pharmaceuticals, Inc., a private biopharmaceutical company focused on developing drugs for pediatric indications.
Tsukamoto, Ann Dr. Ann Tsukamoto serves as Executive Vice President - Research and Development of StemCells Inc. She joined StemCells in November 1997 as Senior Director of Scientific Operations; was appointed Vice President, Scientific Operations in June 1998; Vice President, Research and Development in February 2002; and Chief Operating Officer, with responsibility for the company’s research and development efforts, in November 2006. In October 2008, Dr. Tsukamoto was appointed to the newly created position of Executive Vice President, Research and Development with responsibility for the Company’s scientific and clinical development programs.
Craig, Stewart Dr. Stewart Craig serves as Senior Vice President - Development and Operations of StemCells Inc. He joined StemCells Inc in September 2008 with responsibilities for Development, Manufacturing, Regulatory, Quality Systems and Facilities. From 2005 to 2008, Dr. Craig was Chief Technology Officer and Vice President of Progenitor Cell Therapy, a contract services provider for research, development, manufacture and commercialization of cell-based therapies, prior to which he has held executive positions at Xcyte Therapies, Osiris Therapeutics and SyStemix.
Stratton, Kenneth Mr. Kenneth Stratton joined the StemCells Inc in February 2007 as General Counsel, with responsibility for corporate compliance and legal affairs. In March 2008, he assumed responsibilities for the Human Resources function. Prior to StemCells, Mr. Stratton served as Deputy General Counsel for Threshold Pharmaceuticals and as Senior Legal Counsel for Medtronic’s Vascular business unit.
Weissman, Irving Dr. Irving L. Weissman serves as Director of StemCells Inc since September 1997 and has served as the chairman of the company’s Scientific Advisory Board since that time. Dr. Weissman is the Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor of Pathology and Professor of Developmental Biology at Stanford University. He is also the director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and the director of the Stanford Comprehensive Cancer Center. Previously, Dr. Weissman was a cofounder of SyStemix, Inc. and cofounder and a director of Cellerant Therapeutics, Inc., both stem cell sciences companies. He has also served on the scientific advisory boards of several biotechnology companies, including Amgen, DNAX and T-Cell Sciences. Dr. Weissman is a member of the National Academy of Science, the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences, the American Society of Microbiology, and several other societies.
Perlmutter, Roger Dr. Roger M. Perlmutter serves as Director of StemCells, Inc since December 2000. Dr. Perlmutter is the executive vice president of research and development of Amgen, Inc., a position he has held since January 2001. Prior to joining Amgen, he was the executive vice president of worldwide basic research and preclinical development of Merck Research Laboratories, a division of Merck & Co., Inc., a position he had held since August 1999. He joined Merck in February 1997 as the senior vice president of Merck Research Laboratories, from February 1997 to December 1998 and as its executive vice president from February 1999 to January 2001. Prior to joining Merck, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington from January 1991 to January 1997 and served as chairman of the Department of Immunology at the University of Washington from May 1989 to January 1997. He also was an investigator at the Howard Hughes Medical Institute from October 1991 to January 1997. Dr. Perlmutter was a member of the board of directors of The Irvington Institute for Immunological Research from 1997 to 2001 and of the Institute for Systems Biology, where he has been its chairman of the board since 1999. Dr. Perlmutter is licensed to practice medicine in the State of Washington. He graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University, St. Louis, Missouri in 1979.
Levy, Ricardo Dr. Ricardo B. Levy serves as Director of StemCells Inc since September 2001. Dr. Levy is the lead director of Renegy Holdings, Inc. and has been a member of its board of directors since October 2007. Dr. Levy served as chairman of the board of Catalytica Energy Systems, Inc., between 1995 and 2007 when the company merged to form Renegy. He also served as director of Catalytica Pharmaceuticals Inc. from 1995 to 2000. Prior to this, in 1974, Dr. Levy cofounded Catalytica, Inc., a manufacturing technology and components company. He served as Catalytica’s chief operating officer from 1974 until 1991 and as its president and chief executive officer until December 2000, when Catalytica and Catalytica Pharmaceuticals were both sold to DSM N.V. Before founding Catalytica, Dr. Levy was a founding member of Exxon’s chemical physics research team, and prior to that he served as the chief executive officer of Sudamericana C.A. in Quito, Ecuador. He currently also serves on the board of directors of Accelrys Inc. (formerly Pharmacopeia, Inc.) and NovoDynamics, Inc. Dr. Levy holds an M.S. from Princeton University and a Ph.D. in chemical engineering from Stanford University.
Bjerkholt, Eric Mr. Eric H. Bjerkholt serves as Director of StemCells Inc since March 2004. He is senior vice president and chief financial officer of Sunesis Pharmaceuticals, Inc., a small molecule biopharmaceutical company in South San Francisco, CA. Before joining Sunesis, Mr. Bjerkholt served as the senior vice president and chief financial officer of IntraBiotics Pharmaceuticals, Inc. Previously, Mr. Bjerkholt co-founded LifeSpring Nutrition, Inc., a privately held nutraceutical company, and served as its chief financial officer, and later as its president and chief executive officer. From 1990 to 1997, Mr. Bjerkholt was an investment banker at J.P. Morgan & Co., Inc. Mr. Bjerkholt holds an M.B.A. from Harvard Business School and a Cand. Oecon degree in economics and econometrics from the University of Oslo, Norway. He is a member of the board of directors of Round Table Pizza, Inc.

Basic Compensation

Name Fiscal Year Total
Schwartz, John --
McGlynn, Martin 1,397,600
Young, Rodney 962,895
Tsukamoto, Ann 625,424
Craig, Stewart 103,057
Stratton, Kenneth 422,968
Weissman, Irving --
Perlmutter, Roger --
Levy, Ricardo --
Bjerkholt, Eric --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Schwartz, John 0 0
McGlynn, Martin 1,321,000 2,181,905
Young, Rodney 450,000 0
Tsukamoto, Ann 438,250 640,707
Craig, Stewart 0 0
Stratton, Kenneth 0 0
Weissman, Irving 0 0
Perlmutter, Roger 0 0
Levy, Ricardo 0 0
Bjerkholt, Eric 0 0

Insider Trading

Name Shares Traded Price
PERLMUTTER ROGER M 10,000 $0.00
WEISSMAN IRVING L 10,000 $0.00
LEVY RICARDO B 10,000 $0.00
CRAIG STEWART 93,333 $0.00
TSUKAMOTO ANN 25,000 $1.62
TSUKAMOTO ANN 25,000 $1.19
STRATTON KENNETH BLAIR 93,333 $0.00
MCGLYNN MARTIN M 234,667 $0.00
KOSHY GEORGE 55,600 $0.00
YOUNG RODNEY KB 226,667 $0.00
TSUKAMOTO ANN 93,333 $0.00
KOSHY GEORGE 10,000 $0.61
KOSHY GEORGE 10,000 $1.70
WEISSMAN IRVING L 6,696 $1.70
WEISSMAN IRVING L 43,304 $1.70
KOSHY GEORGE 10,000 $1.61
KOSHY GEORGE 10,000 $0.61
STRATTON KENNETH BLAIR 17,018 $1.65
MCGLYNN MARTIN M 145,344 $1.66
MCGLYNN MARTIN M 57,000 $0.94
TSUKAMOTO ANN 36,816 $1.72
SCHWARTZ JOHN J 88,164 $0.25
YOUNG RODNEY KB 13,292 $1.68
WEISSMAN IRVING L 150,000 $1.72
SCHWARTZ JOHN J 88,164 $1.67
» Full list on Insider Trading
view people for: